For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Tafamidis and Tafamidis meglumine represents a significant advancement . These groundbreaking therapies protect the transthyretin protein, slowing its harmful build-up and lessening the severity of the condition . Patients are now experien